Cupid Raises FY27 Revenue Guidance To ₹800+ Cr And Net Profit To ₹250+ Cr
On September 30, 2026, personal care and healthcare major Cupid Limited revised its FY27 outlook upward. Guided by a strong Q2 expected to top ₹200 crore, the management has hiked its FY27 revenue target to ₹800+ crore and its net profit target to ₹250+ crore. Major growth drivers include the upcoming Palava facility operationalization, South African manufacturing expansion, and strategic warrant conversions in Baazar Style Retail.
Market snapshot: Cupid Limited has significantly upgraded its performance outlook for FY27, raising its revenue guidance to over ₹800 crore and net profit guidance to over ₹250 crore. The revision is supported by robust Q2 FY27 business momentum, where total revenue is expected to cross ₹200 crore, alongside strengthening visibility in international and domestic markets.
Data Snapshot
- FY27 Revenue Guidance raised to ₹800+ crore from previous targets of ₹725-750 crore
- FY27 Net Profit Guidance raised to ₹250+ crore from previous targets of ₹210-225 crore
- Q2 FY27 expected revenue threshold of ₹200+ crore represents accelerating operating scale
What's Changed
- The revenue outlook for FY27 has been sequentially upgraded throughout the year, moving from an initial target of ₹600 crore in June, up to ₹725–750 crore in August, and now finalized at ₹800+ crore.
- Net profit guidance has been elevated to ₹250+ crore from the previously adjusted target of ₹210–225 crore.
- Cupid was officially included in the Nifty Smallcap 250 index, effective September 30, 2026, which is driving passive inflows and expanding its shareholder base.
Key Takeaways
- Accelerating execution is evident as Cupid estimates Q2 revenue will comfortably exceed the ₹200 crore milestone, indicating rapid sequential scale-up.
- The business is entering new markets, supported by an in-principle approval to initiate a South African manufacturing venture using an asset-light operational model.
- Strategic investment conversions are strengthening integration; Cupid approved converting up to 30 lakh warrants of Baazar Style Retail Ltd into shares at ₹328.25 per share to bolster its domestic retail footprint.
- Promoter confidence is strong, highlighted by managing director Aditya Kumar Halwasiya expanding his equity holding via recent open market purchases.
SAHI Perspective
Cupid’s consecutive guidance upgrades highlight a business executing at peak efficiency. By lifting its FY27 revenue target to over ₹800 crore, management is asserting that Q1’s robust performance was structural, not cyclical. Achieving a net profit margin exceeding 31% on this upgraded guidance shows elite operating leverage. Given its WHO/UNFPA pre-qualification moat and incoming capacity from the Palava facility, Cupid’s transition from a pure-play manufacturer to a global FMCG powerhouse is progressing faster than the market anticipated.
Market Implications
The upgraded targets, alongside index inclusion into the Nifty Smallcap 250, are highly favorable for Cupid's valuation multiple. Institutional inflows, estimated by brokerages at around $10 million, will likely boost liquidity. This massive guidance upgrade should help rerate the stock as the company demonstrates top-tier margin profiles and aggressive B2B/FMCG expansion relative to mid-cap peers.
Trading Signals
Market Bias: Bullish
Management's upward guidance revision to ₹800+ crore revenue and ₹250+ crore net profit is strongly supported by Q2 expectations crossing ₹200 crore. Index inclusion on September 30, 2026, acts as a secondary short-term liquidity catalyst.
Overweight: Consumer Healthcare, Personal Care & FMCG
Trigger Factors:
- In-principle approvals for South African asset-light manufacturing expansion
- Official Q2 FY27 earnings filing confirming the ₹200+ crore revenue milestone
- Commercialization progress and operational updates on the Palava facility
Time Horizon: Medium-term (3-12 months)
Industry Context
The global personal care and healthcare procurement industry is experiencing highly stable demand patterns, with international tenders from agencies like UNFPA and WHO providing deep order visibility. Cupid remains structurally advantaged as the first global player with WHO/UNFPA pre-qualification for both male and female condoms. In addition, its domestic FMCG expansion, accelerated by key retail distribution channel partnerships, is efficiently scaling up brand awareness in the high-margin personal care segment.
Key Risks to Watch
- Execution and setup timeline risks associated with the new South African manufacturing facility.
- Exposure to foreign exchange volatility as export sales represent a major segment of the company's operating revenue.
- Fluctuations in government or institutional tender allocation cycles.
Recent Developments
Promoter Aditya Kumar Halwasiya acquired 5,90,304 shares of Cupid Limited on September 28, 2026, raising his direct equity stake to 34.71%. This followed the company's board approving the conversion of up to 30 lakh warrants in Baazar Style Retail Ltd at an exercise price of ₹328.25 per share. Effective September 30, 2026, Cupid shares joined the Nifty Smallcap 250 index.
Closing Insight
With multiple structural growth drivers falling into place simultaneously, Cupid's revised outlook is a strong statement of structural growth and premium profitability in the consumer wellness space.
High Performance Trading with SAHI.
Disclaimer: This news section may include AI-generated or AI-assisted news, summaries, drafts, or insights. All content is subject to human review before publication. While we aim for accuracy, readers should independently verify information before relying on it.
Open Free AccountRelated
JPMorgan Downgrades Apollo Tyres: Navigating Commodity Headwinds and Sector Re-rating
JPMorgan Bullish on TVS Motor: Target Price Hiked to ₹4,440 as Resilience Outshines Sector Risks
JPMorgan Shifts Stance on Escorts Kubota: Upgrade to Neutral Amid Sector Recalibration
Geopolitical Friction in Hormuz: Oil Majors Flag Costs of Proposed Tolls and India’s Readiness Gaps
Recent
Aurobindo Pharma Subsidiary Acrotech Launches Adquey Ointment in US
Symbiotec Subsidiary Knovea Signs US Commercialisation Pact For Two Vial Products
NLC India Subsidiary NIRL Receives LoA For 265 MW/530 MWh Haryana BESS Project
DCM Shriram Commissions 100 TPD Aluminium Chloride and 133 TPD Calcium Chloride Plants
Frequently Asked Questions (FAQs)
All topics
Click the link, confirm the box next to sahi.com is checked — ignore any other results.